Drug Profile
Bovine intestinal alkaline phosphatase - Alloksys Life Sciences
Alternative Names: bIAP; Bovine alkaline phosphatase - Alloksys Life Sciences; bovine RESCAP® - Alloksys; bRESCAPLatest Information Update: 31 Aug 2023
Price :
$50
*
At a glance
- Originator Alloksys Life Sciences
- Class Anti-inflammatories; Anti-ischaemics; Hepatoprotectants; Recombinant proteins
- Mechanism of Action Endotoxin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase III Ischaemia
- Phase II/III Systemic inflammatory response syndrome
- Phase II Burns; Respiratory insufficiency
- No development reported Rheumatoid arthritis
Most Recent Events
- 24 Aug 2023 Alloksys plans to submit a New Drug Application (NDA) and/or Marketing Authorization Application (MAA) in the US and/or Europe
- 24 Aug 2023 Interim efficacy data from the phase II/III trial in Systemic inflammatory response syndrome released by Alloksys
- 24 Aug 2022 Alloksys life sciences initiates enrolment in the phase II trial for Ischaemia (Prevention) in Netherlands (IV, Infusion) (EudraCT2021-006767-14)